ALTO News and Press, Alto Ingredients Inc. From 04/12/22

Biodesix (BDSX) +53%. Actinium Pharmaceuticals ATNM +44% on agreement with Immedica Pharma for conditioning agent. BioCardia BCDA +34% after FDA nod to begin trial of BCDA-04 in COVID patients. Aeglea BioTherapeutics AGLE +19% on filing seeking FDA approval of pe...

Alto Ingredients Inc. (NASDAQ:ALTO) traded today at a new 52-week high of $7.26. This new high was reached on below average trading volume as 674,000 shares traded hands, while the average 30-day volume is approximately 2.9 million shares. Over the past year, Alto Ingredients Inc. has tr...

The S&P materials sector was +4.1% for the week, becoming one of the top gainers among the eleven S&P 500 sectors. The Materials Select Sector SPDR ETF (XLB) also ended the week in green, with a 3.7% growth. Aluminum prices in London jumped at the start of the week...

Alto Ingredients Inc. (NASDAQ:ALTO) traded today at a new 52-week high of $7.14. Approximately 674,000 shares have changed hands today, as compared to an average 30-day volume of 2.7 million shares. In the past 52 weeks, Alto Ingredients Inc. share prices are bracketed by a low of $4.39 ...

Clearside Biomedical (NASDAQ:CLSD) +30% on Q4 results. Pearson (NYSE:PSO) +21% on report Apollo considering making offer for education company. Lazydays Holdings (NASDAQ:LAZY) +19%. 4D pharma (NASDAQ:LBPS) +18%. Superior Drilling Products (NYSE:SDPI) +16% on Q4 r...

Alto Ingredients, Inc. (ALTO) Q4 2021 Results Conference Call March 10, 2022 05:00 PM ET Company Participants Dusty Buell - LHA IR Mike Kandris - CEO Bryon McGregor - CFO Conference Call Participants Eric Stine - Craig-Hallum Amit Dayal - H.C. Wainwright Presentation Operator Ladies and gentl...

Alto Ingredients press release (NASDAQ:ALTO): Q4 GAAP EPS of $0.49. Revenue of $385M. Shares +13.5% AH. For further details see: Alto Ingredients GAAP EPS of $0.49, revenue of $385M

Increased Net Sales 128% to $385 Million and Gross Profit 209% to $42 Million in Q4 2021 vs. Q4 2020 Improved Net Income Available to Common Stockholders to $35 Million from Net Loss of $21 Million and Adjusted EBITDA 168% to $43 Million in Q4 2021 vs. Q4 2020 Grew Net Sales 35% t...

Alto Ingredients (NASDAQ:ALTO) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close. The consensus EPS Estimate is $0.31 (+203.3% Y/Y) and the consensus Revenue Estimate is $323.3M (+91.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revis...

SACRAMENTO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO) , a leading producer and distributor of specialty alcohols and essential ingredients, announced its Pekin, Illinois facility is now ICH Q7 and EXCiPACT Good Manufacturing Practices (GMP) certifi...